Type-I interferons in atherosclerosis

The contribution of dyslipidemia and inflammation in atherosclerosis is well established. Along with effective lipid-lowering treatments, the recent success of clinical trials with anti-inflammatory therapies and the accelerated atherosclerosis in many autoimmune diseases suggest that targeting infl...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Hung-Jen, Tas, Sander W., de Winther, Menno P.J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Rockefeller University Press 2019
Materias:
Reviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7037237/
https://www.ncbi.nlm.nih.gov/pubmed/31821440
http://dx.doi.org/10.1084/jem.20190459

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7037237/
https://www.ncbi.nlm.nih.gov/pubmed/31821440
http://dx.doi.org/10.1084/jem.20190459

Ejemplares similares